2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-153510
    PHD-1-IN-2 2009344-53-8 98%
    PHD-1-IN-2 is an orally active inhibitor of hypoxia-inducible factor prolyl hydroxylase domain 1 (PHD-1) with an IC50 of 0.07 μM. PHD-1-IN-2 acts as a substrate of MDR1 in MDR1-MDCK cell monolayer assays. PHD-1-IN-2 can be used in the research of ischemia, inflammatory responses and neurodegenerative diseases, such as inflammatory bowel disease and ischemia-reperfusion injury.
    PHD-1-IN-2
  • HY-153513
    PHD-1-IN-4 2009343-19-3 99.94%
    PHD-1-IN-4 is a brain-penetrant PHD-1 inhibitor with an IC50 of 0.074 μM.
    PHD-1-IN-4
  • HY-153528
    DMAA 73671-86-0 98%
    DMAA is an indirect sympathomimetic amine. DMAA constricts blood vessels and raises blood pressure. DMAA can be used for neurological and cardiovascular disease research.
    DMAA
  • HY-153548
    P2X2/3 modulator-1 1217483-98-1 98%
    P2X2/3 modulator-1 (Compound 46) is a P2X2/3 modulator. P2X2/3 modulator-1 can be used in the study of pain, central nervous system disorders and inflammation.
    P2X2/3 modulator-1
  • HY-153560
    Lp-PLA2-IN-14 2756855-66-8 98%
    Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC50 of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like.
    Lp-PLA2-IN-14
  • HY-153687
    SORT-PGRN interaction inhibitor 2 1008233-79-1 98%
    SORT-PGRN interaction inhibitor 2 is a SORT-PGRN inhibitor that can decreases SORT1 protein expression and increases extracellular PGRN secretion in mammalian cell lines. SORT-PGRN interaction inhibitor 2 can be used for neurological disease research.
    SORT-PGRN interaction inhibitor 2
  • HY-153688
    SORT-PGRN interaction inhibitor 3 2691846-87-2 98%
    SORT-PGRN interaction inhibitor 3 (Compound 13) is a SORT-PGRN interaction inhibitor (IC50: 0.17 μM). SORT-PGRN interaction inhibitor 3 can be used for research of neurodegenerative diseases.
    SORT-PGRN interaction inhibitor 3
  • HY-153693
    CB2 receptor agonist 4 2052602-31-8 98%
    CB2 receptor agonist 4 (Compound 8) is a highly selective cannabinoid receptor type 2 (CB2 Receptor) agonist with an EC50 of 13.99 nM. CB2 receptor agonist 4 shows no significant activity against cannabinoid receptor type 1. CB2 receptor agonist 4 can be used for the research of pain and immune-related diseases.
    CB2 receptor agonist 4
  • HY-153694
    CB2R agonist-5 2097512-96-2 98%
    CB2R agonist-5 is a selective CB2R agonist with an EC50 of 48.74 nM. CB2R agonist-5 can be used for the research of pain and immune-related diseases.
    CB2R agonist-5
  • HY-153717
    LAU-0901 727358-25-0 98%
    LAU-0901, a PAF receptor antagonist, possesses highly neuroprotective activity. LAU-0901 inhibits apoptosis.
    LAU-0901
  • HY-153746
    Kv3 modulator 5 1380696-68-3 98%
    Kv3 modulator 5 (Example 5) is a Kv3 channel modulator. Kv3 modulator 5 increases the Kv3.2 current. Kv3 modulator 5 can be used for research of hearing disorders.
    Kv3 modulator 5
  • HY-153747
    Casein kinase 1δ-IN-4 851168-98-4 98.0%
    Casein kinase 1δ-IN-4 (compound 567) is a potent casein kinase 1δ inhibitor. Casein kinase 1δ-IN-4 has the potential for the research of Alzheimer's disease.
    Casein kinase 1δ-IN-4
  • HY-153760
    GSK-3β inhibitor 14 863004-48-2 99.92%
    GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak GSK-3β inhibitor (IC50 >100 μM).
    GSK-3β inhibitor 14
  • HY-15381R
    Fingolimod phosphate (Standard) 402615-91-2 98%
    Fingolimod phosphate (Standard) is the analytical standard of Fingolimod phosphate. This product is intended for research and analytical applications. Fingolimod phosphate (FTY720 phosphate) is an orally active sphingosine 1-phosphate (S1P) receptor agonist. Fingolimod phosphate can promote the neuroprotective effects of microglia. Fingolimod phosphate can be used for the research of multiple sclerosis and neurologic diseases.
    Fingolimod phosphate (Standard)
  • HY-153878
    BCAT-IN-4 406190-85-0 98%
    BCAT-IN-4 (Compound 1) is a BCAT inhibitor. BCAT-IN-4 exhibits a moderate ability to inhibit hBCATc with IC50 value of 2.35 μM. BCAT-IN-4 can be used for the research of neurodegenerative diseases.
    BCAT-IN-4
  • HY-153889
    BTA-EG4 921193-28-4 98%
    BTA-EG4 is a catalase-amyloid interaction inhibitor, which can significantly enhance the neurotoxicity of amyloid peptides in catalase-overexpressing neuronal cells, and can be used in the study of neurodegenerative diseases.
    BTA-EG4
  • HY-153904
    Casein kinase 1δ-IN-5 1579991-10-8 98%
    Casein kinase 1δ-IN-5 is a potent and selective protein kinase CK-1δ inhibitor with an IC50 of 47 nM. Casein kinase 1δ-IN-5 shows neuroprotective and anti-inflammatory properties both in vitro. Casein kinase 1δ-IN-5 has the potential for neurodegenerative diseases research.
    Casein kinase 1δ-IN-5
  • HY-153922
    N-Octyl-α-4-epivalienamine 942065-96-5 98%
    N-Octyl-α-4-epivalienamine is an orally active and CNS-penetrant molecular chaperone that induces high expression of the deficient β-galactosidase activity. N-Octyl-α-4-epivalienamine ameliorates symptoms and increase survival rate in a mouse model of GM1-gangliosidosis. N-Octyl-α-4-epivalienamine can be used for neurogenetic disease research.
    N-Octyl-α-4-epivalienamine
  • HY-15394A
    (Rac)-Rotigotine 92206-54-7 98%
    (Rac)-Rotigotine (N-0437) is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
    (Rac)-Rotigotine
  • HY-15394S
    (Rac)-Rotigotine-d7 (hydrochloride) 3026226-88-7 98%
    (Rac)-Rotigotine-d7 (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
    (Rac)-Rotigotine-d7 (hydrochloride)
Cat. No. Product Name / Synonyms Application Reactivity